Long-term stability of recombinant tissue plasminogen activator at -80 C
<p>Abstract</p> <p>Background</p> <p>Recombinant tissue plasminogen activator (tPA) is a thrombolytic widely used clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial infarction, and deep venous thrombosis. This has led to much int...
Main Authors: | Sperling Matthew, Shaw George J, Meunier Jason M |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-06-01
|
Series: | BMC Research Notes |
Online Access: | http://www.biomedcentral.com/1756-0500/2/117 |
Similar Items
-
Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator
by: Sanjith Aaron, et al.
Published: (2020-12-01) -
Stability of Recombinant Tissue Plasminogen Activator at &#8722;30 &#176;C over One Year
by: Abdulmalik Alkatheri
Published: (2013-01-01) -
Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
by: Nancy Kunjukunju, et al.
Published: (2011-02-01) -
Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.
by: Ryu Matsuo, et al.
Published: (2014-01-01) -
Subconjunctival and topical application of recombinant tissue plasminogen activator in rabbits
by: José Ricardo de Abreu Reggi, et al.